BOLERO-4: Phase 2 trial of first-line everolimus (EVE) plus letrozole (LET) in estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC)

Yazar
Debled, M.
Hegg, R.
Cardoso, F.
Ringeisen, F.
Lin, J.
Ridolfi, A.
Manlius, C.
Gradishar, W. J.
Ozguroglu, M.
Royce, M.
Villanueva, C.
Bachelot, T.
Azevedo, S.
Melo Cruz, F.
Üst veri
Tüm öğe kaydını göster
Bağlantı
http://hdl.handle.net/20.500.12627/92345
https://doi.org/10.1093/annonc/mdw365.1
Koleksiyonlar